Diseases of Aging: Q&A with Dr. Thomas Ichim
Dr. Thomas Ichim, president and chief scientific officer at Immorta Bio, spoke with Pharmaceutical Executive about his company’s work focused on age related diseases and the unique challenges this brings.
Dr. Ichim explains how senescent cells, which accumulate with age and following treatments like chemotherapy, play a major role in inflammation, immune dysfunction, and disease progression. Immorta Bio’s platform focuses on senolytic immunotherapies, aiming to selectively eliminate these dysfunctional cells to rejuvenate tissues and restore immune balance.
The company’s lead candidate, SenoVax™, uses autologous dendritic cells loaded with patient-specific senescent antigens to activate a targeted immune response. This approach has shown promise in preclinical models for multiple cancer types and may also have potential applications beyond oncology — including degenerative diseases and aging-associated decline.
Dr. Ichim also touches on the future of personalized medicine and why Immorta’s work sits at the intersection of immunotherapy and regenerative science. As the field of longevity medicine grows, he sees Immorta Bio playing a central role in advancing next-generation therapies for age-related disease.
